The UK Medicines and Healthcare products Regulatory Agency (MHRA) has established a comprehensive, publicly accessible registry documenting all authorised orphan medicinal products available across the National Health Service. This transparent resource represents a significant step toward improving access to rare disease treatments and ensuring systematic communication between regulatory bodies, healthcare professionals, and patients.
The registry serves as a centralised reference tool that enables clinicians to identify evidence-based therapeutic options for rare diseases—defined as conditions affecting fewer than 5 per 10,000 people. By maintaining this definitive public record, the MHRA supports informed prescribing decisions, helps patients understand available treatment pathways, and enables NHS commissioners to make data-driven funding and resource allocation decisions.
Access to this official list removes informational barriers that have historically complicated rare disease management, fostering greater equity in treatment availability across the United Kingdom’s healthcare system.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: UK Orphan Drug Registry Expands Access to Rare Disease Treatments →
